Steward Partners Investment Advisory, LLC Zymeworks Inc. Transaction History

Steward Partners Investment Advisory, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$4.65 - $7.43 $4,650 - $7,430	-1,000 Reduced 86.36%	158 $1,000
Q2 2022 Aug 04, 2022	BUY	$4.82 - $7.7 $4,820 - $7,700	1,000 Added 632.91%	1,158 $6,000
Q4 2021 Feb 08, 2022	SELL	$15.19 - $29.33 $106 - $205	-7 Reduced 4.24%	158 $3,000
Q2 2021 Aug 13, 2021	SELL	$26.5 - $38.23 $18,523 - $26,722	-699 Reduced 80.9%	165 $6,000
Q1 2021 May 14, 2021	SELL	$29.83 - $56.81 $15,929 - $30,336	-534 Reduced 38.2%	864 $27,000
Q4 2020 Feb 11, 2021	SELL	$39.12 - $54.99 $121,467 - $170,743	-3,105 Reduced 68.95%	1,398 $66,000
Q3 2020 Oct 30, 2020	BUY	$29.21 - $46.58 $90,171 - $143,792	3,087 Added 218.01%	4,503 $210,000
Q2 2020 Aug 06, 2020	BUY	$33.67 - $40.0 $33 - $40	1 Added 0.07%	1,416 $51,000
Q1 2020 Apr 29, 2020	BUY	$24.28 - $49.8 $7,526 - $15,438	310 Added 28.05%	1,415 $50,000
Q4 2019 Jan 17, 2020	BUY	$24.84 - $45.46 $21,114 - $38,641	850 Added 333.33%	1,105 $50,000
Q3 2019 Oct 30, 2019	BUY	$22.78 - $29.08 $5,808 - $7,415	255 New	255 $6,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $766M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.